Savara Stock
Savara Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Matthew Pauls
- Employees
- 70
- Market cap
- $914 M
- IPO
- 28/04/2017
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III…
Savara stock: price history
1D
-6.1%
1W
-9.6%
1M
-13.3%
6M
-23.0%
YTD
-26.2%
1Y
+24.3%
2Y
+19.0%
5Y
+245.0%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~27% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Savara
Analyst assessment of Savara
PRICE TARGET LOW
US$10.00
CONSENSUS
US$10.00
MEDIAN
US$10.00
PRICE TARGET HIGH
US$10.00
0
STRONG BUY
9
BUY
2
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 23/12/2025
Savara stock metrics
P/E
-7.67
P/B
7.85
EV/EBITDA
-6.49
RETURN ON EQUITY
-28.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
50.1%
FLOAT SHARES
102,982,510
AVG. DAILY VOLUME (30D)
2,165,788
Insider transactions (SEC)
Parker Braden C.
Lutz Robert Matthew
Lowrance David L
Lowrance David L
Lowrance David L
Attention
1 mention today in US forums, 50% fewer than yesterdayPrice since yesterday: -6.1%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Savara stock
What does Savara do?
Savara Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Matthew Pauls, the company employs around 70 people.
The IPO was on 28/04/2017; the stock trades on NASDAQ under the ticker SVRA.
What do analysts say about Savara stock?
11 analysts rate the stock, the consensus is Buy (as of 23/12/2025).
The average price target is US$10.00, ranging from US$10.00 to US$10.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Savara report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -27% stronger than usual.
Does Savara pay a dividend?
No, Savara currently does not pay a dividend.
Which stocks are comparable to Savara?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Savara stock analyzed?
Clicking "Analyze stock" lets five strategies assess Savara against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.